コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 e and patient type (with vs without systemic lupus erythematosus).
2 or giant cell arteritis to 2.82 for systemic lupus erythematosus).
3 of autoantibodies in patients with systemic lupus erythematosus.
4 cal efficacy in off-label trials of Systemic Lupus Erythematosus.
5 non-coding regions associated with systemic lupus erythematosus.
6 seases, including Crohn disease and systemic lupus erythematosus.
7 -host disease, type 1 diabetes, and systemic lupus erythematosus.
8 osine kinase 2 in a murine model of systemic lupus erythematosus.
9 isease severity in a mouse model of systemic lupus erythematosus.
10 that may limit immune responses in systemic lupus erythematosus.
11 ells in autoimmune diseases such as systemic lupus erythematosus.
12 clerosis, rheumatoid arthritis, and systemic lupus erythematosus.
13 ymorphisms that are associated with systemic lupus erythematosus.
14 utoantibody-driven diseases such as systemic lupus erythematosus.
15 sm for its increased production in cutaneous lupus erythematosus.
16 y be a viable therapeutic target in systemic lupus erythematosus.
17 sis, inflammatory bowel disease and systemic lupus erythematosus.
18 e use of BAFF-targeted therapies in systemic lupus erythematosus.
19 ound in AA, autoimmune uveitis, and systemic lupus erythematosus.
20 hy individuals and in patients with systemic lupus erythematosus.
21 classic mouse model of spontaneous systemic lupus erythematosus.
22 ablasts/PCs in patients with active systemic lupus erythematosus.
23 of intracellular innate sensors in systemic lupus erythematosus.
24 ciated disease in a murine model of systemic lupus erythematosus.
25 stic of autoimmune diseases such as systemic lupus erythematosus.
26 n CD4(+) T cells from patients with systemic lupus erythematosus.
27 ldhood and are also associated with systemic lupus erythematosus.
28 granulocytes from individuals with systemic lupus erythematosus.
29 n implicated in the pathogenesis of systemic lupus erythematosus.
30 uman autoimmune diseases resembling systemic lupus erythematosus.
31 ad to what is clinically defined as systemic lupus erythematosus.
32 ons such as Alzheimer's disease and Systemic Lupus Erythematosus.
33 nal vasculitis or inflammation, and systemic lupus erythematosus.
34 and effective for the treatment of systemic lupus erythematosus.
35 isease, spinocerebellar ataxia, and systemic lupus erythematosus.
36 (high)IL-17A(high) subpopulation of systemic lupus erythematosus.
37 toid arthritis (98.1%), followed by systemic lupus erythematosus (0.79%), psoriasis (0.79%), and scle
38 6.7%]), psoriasis (18 [20.9%]), and systemic lupus erythematosus (12 [14.0%]) were the most common au
40 d inflammatory bowel disease, 2 had systemic lupus erythematosus, 2 had multiple sclerosis, 2 had aut
41 rf21-a gene that is associated with systemic lupus erythematosus(4,5)-interacts with the endolysosoma
42 tibodies that are characteristic of systemic lupus erythematosus, a chronic autoimmune disease with m
43 vated in T cells from patients with systemic lupus erythematosus, a disease characterized by the over
45 toid arthritis, sicca syndrome, and systemic lupus erythematosus (adjusted OR 1.49 [1.34-1.67], 3.47
48 ed with autoimmune diseases such as systemic lupus erythematosus, Aicardi-Goutieres syndrome (AGS) an
49 examined B cells from patients with systemic lupus erythematosus, an autoimmune disorder with a stron
50 ydroxychloroquine used for treating systemic lupus erythematosus and a Syk inhibitor blocked NA-TLR l
51 t can affect the kidneys, including systemic lupus erythematosus and anti-neutrophil cytoplasmic anti
52 r-old woman with recently diagnosed systemic lupus erythematosus and class IV lupus nephritis confirm
54 remarkable for an aunt who died of systemic lupus erythematosus and for a brother with arthritis.
55 ic inflammatory diseases, including systemic lupus erythematosus and inflammatory bowel disease, and
58 present new therapeutic targets for systemic lupus erythematosus and other diseases involving basophi
59 y based on studies in patients with systemic lupus erythematosus and other rheumatic conditions, ther
61 nhibitory pathways in two systemic (systemic lupus erythematosus and rheumatoid arthritis) and two or
63 appa may play a pathogenic role in cutaneous lupus erythematosus and serve as a target for treatment.
64 anti-SSA/Ro autoantibodies, such as systemic lupus erythematosus and Sjogren syndrome, are linked wit
66 E play a role in the development of systemic lupus erythematosus and thus represent new therapeutic t
67 duced in expression in B cells from systemic lupus erythematosus and type 1 diabetes patients, conseq
68 MCD compared with Hodgkin lymphoma, systemic lupus erythematosus, and reactive lymph nodes, suggestin
70 ic anemia (AA), autoimmune uveitis, systemic lupus erythematosus, and sickle cell disease, respective
71 iguring and common manifestation in systemic lupus erythematosus, and the etiology of this predisposi
72 nflammatory skin diseases including systemic lupus erythematosus, angioedema, pemphigus, bullous pemp
73 , we compared the BCR repertoire in systemic lupus erythematosus, anti-neutrophil cytoplasmic antibod
74 pathology observed in patients with systemic lupus erythematosus, autoreactive Abs secreted by autore
75 e implicated in the pathogenesis of systemic lupus erythematosus because they secrete autoantibodies,
76 B cells play an important role in systemic lupus erythematosus by acting not only as precursors of
78 icardi-Goutieres syndrome (AGS) and systemic lupus erythematosus, can arise when TREX1 function is co
81 usion values from all patients with systemic lupus erythematosus correlated positively with systemic
85 ematosus correlated positively with systemic lupus erythematosus disease activity index score (P = 0.
86 activity was determined using the Cutaneous Lupus Erythematosus Disease Area and Severity Index Acti
87 opposing effects in mouse models of systemic lupus erythematosus-disease is exacerbated in TLR9-defic
90 D cells obtained from patients with systemic lupus erythematosus exhibited increased CD45 activity an
91 ent of autoreactive B cells in SLE (systemic lupus erythematosus) focus on extrinsic stimuli and fact
93 lex diseases like Crohn disease and systemic lupus erythematosus, highlighting the value of examining
94 nsion was frequent in patients with systemic lupus erythematosus, in which it correlated to relative
95 y of human rheumatoid arthritis and systemic lupus erythematosus, indicating that increased autophagy
96 as rheumatoid arthritis, diabetes, systemic lupus erythematosus, inflammatory bowel disease, psorias
100 (2020) suggest that the IFN signature in lupus erythematosus (LE) alters expression of epithelial
103 Evaluation of discoid and subacute cutaneous lupus erythematosus lesions showed significant epidermal
106 scular/autoimmune disorders such as systemic lupus erythematosus; lymphoproliferative disorders such
107 rheumatoid arthritis (n = 25,324), systemic lupus erythematosus (n = 3,951), and/or vasculitis (n =
108 ials are the primary treatment for cutaneous lupus erythematosus, not all patients are equally respon
111 s who care for patients with severe systemic lupus erythematosus or catastrophic antiphospholipid syn
112 -driven autoimmune diseases such as systemic lupus erythematosus or psoriasis, but pDCs are also invo
116 inflammatory DC3s were expanded in systemic lupus erythematosus patients and correlated with disease
117 cytic Siglec-1 expression in active systemic lupus erythematosus patients and, additionally, revealed
118 ons that emerge from the B cells of systemic lupus erythematosus patients can be restored by GA stimu
123 om human healthy controls and human systemic lupus erythematosus patients, metformin inhibits the tra
124 myasthenia gravis patients, and six systemic lupus erythematosus patients, obtained by next-generatio
125 od mononuclear cells isolated from cutaneous lupus erythematosus patients, whereas QC and HCQ inhibit
130 inical autoimmunity and established systemic lupus erythematosus, plasmacytoid dendritic cells are no
131 soriasis, rheumatoid arthritis, and systemic lupus erythematosus predispose to atherosclerotic cardio
133 ated with type I diabetes mellitus, systemic lupus erythematosus, RA, and celiac disease, these resul
134 between SJS/TEN and pre-existing depression, lupus erythematosus, recent pneumonia, chronic kidney di
135 0.18 +/- 0.07, P = 7.78 x 10-3) and systemic lupus erythematosus (rg = 0.13 +/- 0.05, P = 3.76 x 10-3
136 and autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis and systemic s
138 urrent and future impact of AMDs on systemic lupus erythematosus, rheumatoid arthritis, and devastati
139 immune connective tissue disorders: systemic lupus erythematosus, rheumatoid arthritis, systemic scle
142 s, such as rheumatoid arthritis and systemic lupus erythematosus, show a polygenic inheritance patter
143 disorder; systemic diseases such as systemic lupus erythematosus, Sjogren syndrome or Behcet disease
144 and cytokine profiles in lesional cutaneous lupus erythematosus skin could affect antimalarial respo
145 tes (T1D) (n = 200, HD n = 200), 3) systemic lupus erythematosus (SLE) (n = 200, HD n = 67; neuro-SLE
146 nterferon (IFN) drives pathology in systemic lupus erythematosus (SLE) and can be tracked via IFN-ind
147 n C1q deficiency is associated with systemic lupus erythematosus (SLE) and increased susceptibility t
149 oimmune rheumatic diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA),
150 gen in autoimmune disorders such as systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS).
151 r instance, the autoimmune diseases systemic lupus erythematosus (SLE) and Sjogren's syndrome affect
152 ritis (RA), osteoarthritis (OA), or systemic lupus erythematosus (SLE) and to identify metabolites as
154 s in lupus models and patients with systemic lupus erythematosus (SLE) arise as a consequence of defe
155 and IL-23 receptor in patients with systemic lupus erythematosus (SLE) as compared with healthy contr
156 lating Tfh cells from patients with systemic lupus erythematosus (SLE) but not primary antiphospholip
157 to be the major IFNalpha source in systemic lupus erythematosus (SLE) but their phenotype and functi
160 of gene expression data to predict systemic lupus erythematosus (SLE) disease activity is a signific
167 nd clinical trials in patients with systemic lupus erythematosus (SLE) has caused a profound sense of
170 effects on autoimmune diseases like systemic lupus erythematosus (SLE) have yet to be investigated.
172 tes, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) increase susceptibility to des
204 ion-based studies have been done on systemic lupus erythematosus (SLE) mortality trends in the United
208 Despite advances in understanding systemic lupus erythematosus (SLE) pathogenesis, most clinical tr
210 rize total serum antibody Fabs in a systemic lupus erythematosus (SLE) patient sample and compared it
211 12.31 was replicated in a cohort of systemic lupus erythematosus (SLE) patients (N = 47) and controls
213 mplicated lymphocytes isolated from systemic lupus erythematosus (SLE) patients compared to healthy c
214 ity landscape of naive B cells from Systemic Lupus Erythematosus (SLE) patients undergoing disease fl
215 etiology of the autoimmune disorder systemic lupus erythematosus (SLE) remains poorly understood.
217 ve been found to be associated with systemic lupus erythematosus (SLE) susceptibility by a recent gen
218 come of 39 variants associated with Systemic Lupus Erythematosus (SLE) through the integration of GWA
219 hritis is a common manifestation of systemic lupus erythematosus (SLE) yet understanding of the under
221 are disproportionately affected by systemic lupus erythematosus (SLE), a chronic, potentially debili
222 role in autoimmune diseases such as systemic lupus erythematosus (SLE), a condition characterized by
223 IRF5 are associated with a risk of systemic lupus erythematosus (SLE), and mice lacking Irf5 are pro
224 ncy (CVID), Evans syndrome (ES), or systemic lupus erythematosus (SLE), and most achieved a CR (N = 8
225 sis in autoimmune diseases, such as systemic lupus erythematosus (SLE), but the natural history of au
226 n human autoimmune diseases such as systemic lupus erythematosus (SLE), but the underlying mechanisms
227 7 is associated with development of systemic lupus erythematosus (SLE), but the underlying mechanisms
229 nesis of autoimmunity, most notably systemic lupus erythematosus (SLE), diabetes mellitus, and dermat
230 with smoking, hyperopia, diabetes, systemic lupus erythematosus (SLE), greater deprivation (Townsend
232 t contribute to the pathogenesis of systemic lupus erythematosus (SLE), including autoreactive B cell
233 e of autoimmune diseases, including systemic lupus erythematosus (SLE), is an increased prevalence in
237 eral autoimmune diseases, including systemic lupus erythematosus (SLE), Sjogren's syndrome, inflammat
239 the susceptibility and severity of systemic lupus erythematosus (SLE), using renal disease as a prox
240 7 (TLR7)-dependent mouse models of systemic lupus erythematosus (SLE), we dissect dietary effects on
241 nked to autoimmune diseases such as systemic lupus erythematosus (SLE), where nucleic acid-containing
242 choroidal changes in patients with systemic lupus erythematosus (SLE), with or without glomeruloneph
243 utoimmune diseases, with a focus on systemic lupus erythematosus (SLE), with the relevant translation
244 NA) are prevalent and pathogenic in systemic lupus erythematosus (SLE), yet mechanisms of their devel
245 aneous inflammation is recurrent in systemic lupus erythematosus (SLE), yet mechanisms that drive cut
247 lls (LysM(Cre)Bim(fl/fl)) develop a systemic lupus erythematosus (SLE)-like disease that mirrors aged
248 actor T-bet promote autoimmunity in Systemic Lupus Erythematosus (SLE)-prone mouse models, the role f
280 ts are associated with the risk for systemic lupus erythematosus (SLE); however, it is unclear how Ox
281 in the inflammation associated with systemic lupus erythematosus (SLE); however, it remains unclear w
282 F) and plasma from 35 patients with systemic lupus erythematosus (SLE; 15 with NPSLE) showed no antib
283 atients with systemic sclerosis and systemic lupus erythematosus, suggesting a way to characterize CD
284 connective tissue diseases, such as systemic lupus erythematosus, systemic sclerosis, and myositis.
285 ases, such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, vasculitis or i
286 s (LN) is a common manifestation of systemic lupus erythematosus that can lead to irreversible renal
287 neuropathy, Sjogren's syndrome, and systemic lupus erythematosus that have been controlled with immun
288 psoriasis to alopecia areata to vitiligo to lupus erythematosus to atopic dermatitis and food allerg
291 ients with rheumatoid arthritis and systemic lupus erythematosus were demethylated compared to health
292 d model of autoimmunity, similar to systemic lupus erythematosus, where both cell types are critical
293 tions in the brain of patients with systemic lupus erythematosus with and without a history of centra
294 eficiency causes familial monogenic systemic lupus erythematosus with childhood onset and anti-dsDNA
295 corpus callosum of 13 patients with systemic lupus erythematosus with past NPSLE, 16 patients with sy
297 h disease activity in patients with systemic lupus erythematosus with plasmablast-associated flares.
298 ons were made between patients with systemic lupus erythematosus with/without past NPSLE and healthy
299 f the most severe manifestations of systemic lupus erythematosus, with considerable morbidity and mor
300 s with past NPSLE, 16 patients with systemic lupus erythematosus without past NPSLE, and 19 healthy c